Cargando…

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease

BACKGROUND AND OBJECTIVES: Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to evaluate the pharmacokinetic properties of once-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubino, Christopher M., Onufrak, Nikolas J., van Ingen, Jakko, Griffith, David E., Bhavnani, Sujata M., Yuen, Dayton W., Mange, Kevin C., Winthrop, Kevin L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935831/ https://www.ncbi.nlm.nih.gov/pubmed/33595792 http://dx.doi.org/10.1007/s13318-020-00669-7

Ejemplares similares

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
por: Winthrop, Kevin L., et al.
Publicado: (2021)

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
por: Khan, Omer, et al.
Publicado: (2020)

805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
por: Brown-Elliott, Barbara A, et al.
Publicado: (2018)

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
por: Zhang, Jimin, et al.
Publicado: (2018)

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis
por: Kidogawa, Moe, et al.
Publicado: (2022)

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022)

Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience
por: Chiron, Raphael, et al.
Publicado: (2022)

Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
por: Chalmers, James D., et al.
Publicado: (2021)

Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
por: Henriette Zweijpfenning, Sanne Maria, et al.
Publicado: (2022)

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

The epidemiology of nontuberculous mycobacterial pulmonary disease in the Netherlands
por: Schildkraut, Jodie Anne, et al.
Publicado: (2021)

Laryngitis after inhalation of liposomal amikacin
por: Morita, Atsuho, et al.
Publicado: (2022)

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Hospitalization Risk for Medicare Beneficiaries With Nontuberculous Mycobacterial Pulmonary Disease
por: Prevots, D. Rebecca, et al.
Publicado: (2021)

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada
por: Aznar, Maria Luisa, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
por: Jin, Xuanyou, et al.
Publicado: (2020)

Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey
por: Swenson, Colin, et al.
Publicado: (2020)

Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration
por: Jones, Makoto M., et al.
Publicado: (2018)

1417. Evaluating the Dissonance Between C(max) and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study
por: Onufrak, Nikolas J, et al.
Publicado: (2018)

Species Distribution and Isolation Frequency of Nontuberculous Mycobacteria, Uruguay
por: Greif, Gonzalo, et al.
Publicado: (2020)

780. Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in US Medicare, 2008–2015
por: Winthrop, Kevin L, et al.
Publicado: (2018)

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients
por: Caimmi, Davide, et al.
Publicado: (2018)

Delivery of Aerosolized Liposomal Amikacin as a Novel Approach for the Treatment of Nontuberculous Mycobacteria in an Experimental Model of Pulmonary Infection
por: Rose, Sasha J., et al.
Publicado: (2014)

Nontuberculous mycobacterial osteomyelitis
por: Bi, Sheng, et al.
Publicado: (2015)

Global survey of physician testing practices for nontuberculous mycobacteria
por: Loebinger, Michael R., et al.
Publicado: (2023)

122. All-Cause Mortality Increased With Nontuberculous Mycobacterial Lung Disease in US Medicare
por: Marras, Theodore, et al.
Publicado: (2018)

Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings
por: Aksamit, Timothy, et al.
Publicado: (2022)

1389. Nontuberculous Mycobacterial Infections of the Upper Extremity
por: Polveroni, Thomas M, et al.
Publicado: (2021)

Time-to-positivity of Mycobacterium avium complex in broth culture associates with culture conversion
por: Mingora, Christina M., et al.
Publicado: (2022)

The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
por: Yagi, Kazuma, et al.
Publicado: (2017)

Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008–2015
por: Winthrop, Kevin L., et al.
Publicado: (2020)

192. Tolerability Outcomes of Multi-drug Antibiotic Treatment for Pulmonary Nontuberculous Mycobacterial Disease due to Mycobacterium avium Complex in U.S. Medicare Beneficiaries with Bronchiectasis
por: Ku, Jennifer, et al.
Publicado: (2021)

Recurrent Nontuberculous Mycobacterial Tenosynovitis
por: Kwan, Melissa, et al.
Publicado: (2021)

Profiling mycobacterial communities in pulmonary nontuberculous mycobacterial disease
por: Cowman, Steven A., et al.
Publicado: (2018)

Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and Effect on Macrophage Function after Administration in Rats
por: Malinin, Vladimir, et al.
Publicado: (2016)

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report
por: Hashimoto, Kazuki, et al.
Publicado: (2023)

Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010
por: Marras, Theodore K., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_aegr6mr9dcqta7nh7a1sv9er6i